A revolutionary drug , retatrutide, is sparking considerable anticipation within the Australian weight control community. Developed by Eli Lilly , this twin GIP and GLP-1 agonist appears to offer more significant benefits than present therapies. Preliminary clinical research have shown exceptional decreases in body mass, raising the potential for a